| View Larger Image | Early initiation of highly active antiretroviral therapies for AIDS: Dynamic choice with endogenous and exogenous learning [An article from: Journal of Health Economics] | Digitalby P. Lasserre (Author), J.P. Moatti (Author), A. Soubeyran (Author)
| List Price: | $10.95 | | | Available: | Available for download now |
| | Binding: | Digital | | Publisher: | Elsevier | | Page Count: | 19 Pages | | Publication Date: | May 01, 2006 |
|
EDITORIAL REVIEWS |
Product Description
This digital document is a journal article from Journal of Health Economics, published by Elsevier in 2006. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.Description: Criteria for initiation of highly active antiretroviral treatments (HAART) in HIV-infected patients remain a matter of debate world-wide because short-term benefits have to be balanced with costs of these therapies, and restrictions placed on future treatment options if resistant viral strains develop. On the other hand, postponing the introduction of HAART may involve a therapeutic opportunity cost if a patient's health is allowed to deteriorate to such an extent of becoming unable to benefit from new treatments currently under development when they become available. We introduce a two period model where period one treatment adoption is an irreversible act with future, but uncertain, consequences. New information, both endogenous and exogenous, arises over time and shapes the conditions surrounding the second period therapeutic decision. A surprising result is that, under conditions that appear close to those surrounding the HAART debate, the magnitude of the feared resistance effect has no effect on leaves the optimal treatment decision as far as it is high enough. JEL classification: I18; C61 Keywords: Therapeutic decisions; Uncertainty; Information; Irreversibility; Treatment Resume Le bien-fonde d'administrer precocement des traitements antire troviraux a haute activite (HAART) aux personnes infectees par le VIH reste objet de debats dans le monde car leurs bienfaits a court terme peuvent compromettre les traitements futurs si se de veloppent des souches resistantes du virus. Par ailleurs retarder le recours aux HAART comporte un cout d'opportunite therapeutique si la sante du patient se degrade au point qu'il ne peut plus ben eficier par la suite des traitements encore en cours de de veloppement. Nous formulons un modele a deux periodes ou l'adoption du traitement de premiere periode est irreversible et engage le futur, alors que des informations et connaissances nouvelles, exog enes et endogenes, determinent les conditions entourant la de cision therapeutique de deuxieme periode. Paradoxalement, sous des conditions refletant bien les enjeux du recours aux HAART, il s'av ere que l'effet resistance eventuel a d'autant moins de chance d'importer pour la decision optimale, que sa gravite est elev ee. on optimale, que sa gravite est elev ee. |
|
![Early initiation of highly active antiretroviral therapies for AIDS: Dynamic choice with endogenous and exogenous learning [An article from: Journal of Health Economics]](http://ecx.images-amazon.com/images/I/51QFPM7B0KL._SL160_.jpg)
